col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Oxford University Press: Journal of Crohn s and Colitis
  original article Date Title Authors   All Authors
1 [GO] 2021―Jun―14 Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease Edoardo G Giannini, Maria Giulia Demarzo, Giorgia Bodini
2 [GO] 2021―May―28 P610 Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions B Z S Lo, A Mokrowiecka, A Mikocka-Walus, C N Bernstein, I A Trindade, J Burisch, et al. (+4)
3 [GO] 2021―May―28 P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID) J Geldof, M Truyens, J Sabino, M Ferrante, J Lambert, H Lapeere, et al. (+6)
4 [GO] 2021―May―28 DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study Y Zabana Abdo, I Marín-Jiménez, I Rodríguez-Lago, I Vera, M D Martín, I Guerra, et al. (+34)
5 [GO] 2021―May―28 P612 Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study F Ferretti, M C Monico, A M Carvalhas Gabrielli, S Carmagnola, C Bezzio, S Saibeni, et al. (+18)
6 [GO] 2021―May―28 P642 Effects of Covid-19 on employment in IBD patients M Sciberras, C Nascimento, T Tabone, K Karmiris, P Nikolaou, A Theodoropoulou, et al. (+16)
7 [GO] 2021―May―28 P145 Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg) M Rottoli, G Pellino, M Tanzanu, C Baldi, A Frontali, M Carvello, et al. (+12)
8 [GO] 2021―May―28 P401 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study C A Lamb, S Sebastian, A J Kent, J P Segal, H A Gonzalez, M J Brookes, et al. (+8)
9 [GO] 2021―May―28 P186 Inflammatory Bowel Disease Care in the Covid-19 pandemic era: Experience from a Tunisian gastroenterology department W Dahmani, N Sahar, H Aya, E Nour, B A Wafa, B S Aida, et al. (+4)
10 [GO] 2021―May―28 P641 Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease S García Mateo, E Refaie, S J Martínez-Domínguez, C J Gargallo-Puyuelo, L Lario Quilez, P Carrera-Lasfuentes, et al. (+3)
11 [GO] 2021―May―28 P541 Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown L Ramos Lopez, C Reygosa, M Carrillo-Palau, I Alonso-Abreu, Y González, R de la Barreda, et al. (+4)
12 [GO] 2021―May―28 P185 Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain A Hernandez Camba, L Ramos, M B Madrid Álvarez, L Pérez-Méndez, P Nos, V Hernández, et al. (+10)
13 [GO] 2021―May―28 P648 Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease L Lindoso, J Oba, L C A Miranda, M Deboni, M Jiro Ozaki, D C C Lima, et al. (+6)
14 [GO] 2021―May―28 Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU Y Zabana Abdo, I Marín-Jiménez, I Rodríguez-Lago, F Ramírez Esteso, S Meijilde, L Ramos, et al. (+34)
15 [GO] 2021―May―28 P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study M Calafat Sard, C González-Muñoza, M Fortuny, C Roig, A Calm, A Mombiela, et al. (+8)
16 [GO] 2021―May―28 P625 Characteristics of SARS-CoV-2 infection in IBD patients in the second and third wave compared with the first wave and with the data of general population I Guerra Marina, A Algaba, S Castro, L Jiménez, D Garza, M D M Aller, et al. (+5)
17 [GO] 2021―May―28 P611 Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection A Algaba Garcia, I Guerra, S Castro, L Jiménez, D Garza, M D M Aller, et al. (+5)
18 [GO] 2021―May―28 P623 The impact of SARS-CoV-2 outbreak on the treatment adherence and clinical outcome of patients with inflammatory bowel disease treated with biological agents G Martino, S Carparelli, A Marseglia, M R Pastore, M Placentino, M Nardella, et al. (+6)
19 [GO] 2021―May―28 P626 SARS-CoV-2 seroprevalence in patients with Inflammatory Bowel Disease S García Mateo, S J Martínez-Domínguez, M C Aso Gonzalvo, C J Gargallo-Puyuelo, B Gallego Llera, M T Arroyo Villarino, et al. (+6)
20 [GO] 2021―May―28 P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic S Lin, C Bewshea, N Chanchlani, D Chee, R C Pollok, N A Kennedy, et al. (+2)
21 [GO] 2021―May―28 P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments A J Walsh, L Matini, J Wilson, S Lyden, L Al-Hillawi, R Kantschuster, et al. (+11)
22 [GO] 2021―May―27 N03 Information flow experiences during COVID-19 in IBD patients: a prospective observational study P Geens, E De Dycker, A Paps, T Lambrechts, J Sabino, M Ferrante, S Vermeire
23 [GO] 2021―May―27 P578 Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients V Borzan, V Orsic Fric, B Borzan
24 [GO] 2021―May―27 P637 Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting A Rezazadeh Ardabili, R H Creemers, D M A E Jonkers, M J L Romberg-Camps, M J Pierik, A A van Bodegraven
25 [GO] 2021―May―27 P636 The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD G Bamias, G Kokkotis, D Christodoulou, V Delis, A Gatopoulou, O Giouleme, et al. (+26)
26 [GO] 2021―May―27 P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience L Lichtenstein, B Koslowsky, I Avni-Biron, B Ovadia, O Ben-Bassat, T Naftali, et al. (+34)
27 [GO] 2021―May―27 DOP77 Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli Experience V Richter, A Bermont, D L Cohen, E Broide, H Shirin
28 [GO] 2021―May―27 P143 Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown L Sempere Robles, P Bernabeu, J Cameo, A Gutiérrez, G García, M F García, et al. (+4)
29 [GO] 2021―May―27 P385 Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown T Paupard, C Richez, J Verlynde, O Zaharia, G Quartier, H Hudziak, L Delhoustal
30 [GO] 2021―May―27 P093 COVID-19 lockdown and mental health burden in Inflammatory Bowel Disease paediatric patients: a case-control study F Milo, E F Romeo, F Rea, T Grimaldi Capitello, P De Angelis, P Tabarini
31 [GO] 2021―May―27 P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States R Ungaro, B Chou, J Mo, L Ursos, R Twardowski, N Candela, J F Colombel
32 [GO] 2021―May―27 DOP76 No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD G Funez-dePagnier, S Lima, L Duenas-Bianchi, D Lai, W Ahmed, R Battat, et al. (+3)
33 [GO] 2021―May―27 P620 Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease - A retrospective study G Malhi, J Chambers, G Minhas, M Mikail, R Khanna, A Wilson
34 [GO] 2021―May―27 P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic H Guo, J Tang, Z Huang, B Li, Q Yang, K Chao, X Gao
35 [GO] 2021―May―27 P178 Remote monitoring as an effective management strategy in inflammatory bowel disease: the lesson from COVID-19 pandemic A Busacca, E Sinagra, L Guida, L Carrozza, M Melodia, M Maida, et al. (+4)
36 [GO] 2021―May―27 P638 Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain? J Del Hoyo Francisco, M Millán, A Garrido-Marín, P Nos, M Barreiro-de Acosta, L Bujanda, et al. (+2)
37 [GO] 2021―May―27 P434 Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period S Hu, X Wang, B Shen, Q Yu, J J Zheng, Y Chen
38 [GO] 2021―May―27 N10 Experience with telemedicine during the COVID-19 pandemic and preferences for future e-health in a large IBD cohort S Breiteneicher, T G Le Thi, E Klucker, T Schwerd, K Csollarova, L Neuhaus, et al. (+3)
39 [GO] 2021―May―27 P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID D Edwards, M Ibrahim, R Cooney, R Boulton
40 [GO] 2021―May―27 P341 Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel Disease L Koletzko, E Klucker, G Le Thi, S Breiteneicher, R Rubio-Acero, L Neuhaus, et al. (+6)
41 [GO] 2021―May―27 P258 Rates of admission of acute IBD flares during the COVID-19 pandemic in a tertiary healthcare setting K Hazel, E Glynn, K Boland, A O’Toole
42 [GO] 2021―May―27 P525 Patients’ Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel O Lior, I Sergeev, N Ruhimovich, M Openheim, F Benjaminov, D Feldman, et al. (+2)
43 [GO] 2021―May―27 P490 The impact of the COVID-19 pandemic on gastroenterologists providing care to inflammatory bowel disease patients in Canada: preliminary data of a cross-sectional survey M Mikail, G Malhi, A Wilson, R Khanna
44 [GO] 2021―May―27 P163 The impact of the COVID-19 pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease in The Netherlands E Paulides, A Pasma, N S Erler, R L A van Eijk, A C de Vries, C J van der Woude
45 [GO] 2021―May―27 N06 Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit G Dewitte, J Geldof, M Truyens, T Lobaton
46 [GO] 2021―May―27 P136 Management of patients with Inflammatory Bowel Disease and their outcome during the first wave of Covid-19 pandemics A Viola, F Giambò, M F Chiappetta, G Costantino, S Pallio, G Navarra, et al. (+2)
47 [GO] 2021―May―27 P503 Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics A Todeschini
48 [GO] 2021―May―27 DOP90 Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 years A Ricciuto, C Lamb, E I Benchimol, G Walker, N Kennedy, M E Kuenzig, et al. (+4)
49 [GO] 2021―May―27 P362 Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics S Y Wong, R Dixon, S Gold, M Vicky, D Helmus, K Cadwell, J F Colombel
50 [GO] 2021―May―27 P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus) A Costantino, D Noviello, F S Conforti, M Aloi, A Armuzzi, F Bossa, et al. (+12)
51 [GO] 2021―May―27 P657 Acceptability of a COVID-19 vaccine among cohort of Croatian IBD patients treated in tertiary IBD centre V Tomasic, A Bišćanin, P Ćaćić, D Kralj, Z Dorosulić, D Ogresta, D Hrabar
52 [GO] 2021―May―27 P128 Depression, anxiety and stress among Inflammatory Bowel Disease patients during COVID-19: A UK cohort study R Luber, A Duff, P Pavlidis, S Honap, S Meade, S Ray, et al. (+4)
53 [GO] 2021―May―27 OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry R Ungaro, E Brenner, M Agrawal, R B Gearry, G G Kaplan, M Kissous-Hunt, et al. (+8)
54 [GO] 2021―May―27 P171 Immune-mediated diseases (IMID) and COVID-19: results from an observational retrospective multicenter study C Calviño Suárez, R Dos-Santos, I Baston-Rey, F J Montero, R Ferreiro-Iglesias, I Marin-Jimenez, et al. (+3)
55 [GO] 2021―May―27 P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications- A Danish prospective population-based cohort study M Attauabi, A Poulsen, M Kajbæk Verner-Andersen, M Rosager Hansen, N Pedersen, A Pilegaard Prahm, et al. (+18)
56 [GO] 2021―May―27 P359 Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection O Knyazev, A Kagramanova, A Lishchinskaya, K Noskova, M Chernova, T Shkurko, et al. (+4)
57 [GO] 2021―May―27 P351 SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn’s disease: single tertiary center experience M Sładek, M Krucka-Kawalec, E Wojtas, P Jagielski, A Stochel-Gaudyn
58 [GO] 2021―May―27 P666 Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy T Resál, K Farkas, T Molnár
59 [GO] 2021―May―27 P112 Impact of the SARS-COV2 pandemic on patients with inflammatory bowel disease - Preliminary results of a prospective, single-center study L Martins Figueiredo, F Correia, M A Rafael, L Lourenço, A M Oliveira, J C Branco, et al. (+2)
60 [GO] 2021―May―27 P457 Long-term follow-up of patients with IBD after switching from original adalimumab to adalimumab biosimilar during COVID 19 pandemic K Klimova, C Padilla Suarez
61 [GO] 2021―May―27 P488 The COVID19 pandemic impact on Inflammatory Bowel Disease Patients Management in a Romanian Tertiary Gastroenterology Centre R Costache, R Iacob, R Vadan, T Stroie, L Gheorghe, M Diculescu, C Gheorghe
62 [GO] 2021―Mar―13 SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges Judith Wellens, Jean-Frédéric Colombel, Jack J Satsangi, Serre-Yu Wong
63 [GO] 2020―Nov―18 Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy Roberto Berte', Stefano Mazza, Marta Rachele Stefanucci, Daniele Noviello, Stefania Costa, Clorinda Ciafardini, et al. (+11)
64 [GO] 2020―Oct―28 COVID-19 in the IBD population: The need for correct nomenclature Ashkan Rezazadeh Ardabili, Rob H Creemers, Adriaan A van Bodegraven
65 [GO] 2020―Sep―28 Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in a patient receiving Infliximab therapy for Inflammatory Bowel Disease Joseph Meredith, Cher-Antonia Khedim, Paul Henderson, David C Wilson, Richard K Russell
66 [GO] 2020―Sep―17 Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force Iris Dotan, Remo Panaccione, Gilaad G Kaplan, Colm O’Morain, James O Lindsay, Maria T Abreu
67 [GO] 2020―Sep―14 Letter to the Editor: Care of the Patient with IBD Requiring Hospitalisation During the COVID-19 Pandemic Aysha H Al-Ani, Ralley E Prentice, Britt Christensen
68 [GO] 2020―Sep―09 Prevalence of COVID-19 Symptoms among Inflammatory Bowel Disease Patients Treated with Biological Agents Thomas E Conley, Chris Probert, Sreedhar Subramanian
69 [GO] 2020―Aug―24 Conducting Translational Gastrointestinal Research in the Era of COVID-19 S Nayeri, M Walshe, S Lee, M Filice, S Rho, A Jeyakumar, et al. (+3)
70 [GO] 2020―Aug―07 Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic Walter Reinisch, Silvio Danese, Laurent Peyrin-Biroulet, Edward V Loftus
71 [GO] 2020―Jun―23 Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom Nurulamin M Noor, Ailsa L Hart, Peter M Irving, Subrata Ghosh, Miles Parkes, Tim Raine
72 [GO] 2020―Jun―07 Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD S Sebastian, H A Gonzalez, L Peyrin-Biroulet
73 [GO] 2020―May―28 Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report Reiko Kunisaki, Jun Tsukiji, Makoto Kudo
74 [GO] 2020―Apr―15 Impact of anti-tnfα antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases Antonio Tursi, Alfredo Papa
75 [GO] 2020―Apr―15 Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn’s Patients, Due to a Lower Rate of Smokers? Carina Peyrin-Biroulet, Ferdinando D’Amico, Laurent Peyrin-Biroulet
76 [GO] 2020―Mar―27 COVID-19 outbreak and inflammatory bowel disease management: a questionnaire survey from realistic practice Xiaoyin Bai, Hong Yang, Jiaming Qian
77 [GO] 2020―Mar―23 Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? Giovanni Monteleone, Sandro Ardizzone
78 [GO] 2020―Mar―19 Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience Gionata Fiorino, Mariangela Allocca, Federica Furfaro, Daniela Gilardi, Alessandra Zilli, Simona Radice, et al. (+2)


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.005 sec